Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SanJoint UC is a branded pharmaceutical and nutraceutical product developed by Sanrey Therapeutics, an Indian pharmaceutical company based in Chennai. It is specifically formulated for orthopedic and rheumatological applications, primarily the management of osteoarthritis, rheumatoid arthritis, and chronic joint pain. The active ingredient, Undenatured Type II Collagen (UC-II), is a protein derived from chicken sternum cartilage that retains its native triple-helix structure. Unlike hydrolyzed collagen, which is broken down into peptides, UC-II functions via a mechanism known as oral tolerance. Upon ingestion, it interacts with gut-associated lymphoid tissue (GALT), specifically Peyer's patches in the small intestine. This interaction triggers the production of regulatory T cells (Tregs) specific to Type II collagen. These cells then migrate to the joints, where they release anti-inflammatory cytokines such as IL-10 and TGF-beta, helping to suppress the immune-mediated destruction of joint cartilage and promoting joint mobility and comfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SanJoint UC.